ATAGI releases Novavax guidance for adolescents The new advice means adolescents aged 12–17 years will have another COVID-19 vaccine option from 5 September.
TGA green lights Nuvaxovid for 12–17-year-olds But while provisional approval has been granted, inclusion in the national program for this age group is yet to be confirmed.
Novavax receives COVID-19 booster approval The protein-based vaccine is the third to gain TGA approval as a booster in Australia, following Pfizer and Moderna.
TGA releases vaccine-related myocarditis severity details Fewer than 1% of all likely myocarditis or pericarditis cases linked to mRNA vaccines in Australia have been treated in intensive care.
First safety data on Novavax released Early information on the administration of the Novavax vaccine in Australia is in line with clinical trials data, the TGA has reported.
Novavax given limited approval as booster New ATAGI advice permits Novavax for third dose and encourages those who had AstraZeneca as primary course to take mRNA booster.
How many people were ‘waiting for Novavax’? The approval of Novavax was long-awaited. Now its rollout is under way, newsGP assesses what response GPs are seeing on the ground.
Novavax rollout fast-tracked After months of delays, the rollout of Australia’s fourth COVID vaccine began over the weekend.
ATAGI rules on Novavax The long-awaited vaccine will be available from 21 February, but the RACGP has said general practice needs more support for the rollout.
Novavax approval: what it means for GPs The TGA’s Professor John Skerritt hopes the availability of the new vaccine will push the vaccination rate in Australia even higher.